Company / Capital Expenditures
BioRestorative Therapies, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$116.1K
FY2025
5-year range
$30.7K / $265.2K
FY2021-FY2025
Trend
-32.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 10 years, ranging from $3,617 in FY2018 to $408,069 in FY2016.
Based on SEC 10-K filings.
$116,069 in FY2025 with a 5-year CAGR of +26.6%.
Declined from $171,043 to $116,069 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -24.1%
- 5-Year CAGR
- +26.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +26.6%, indicating consistent growth.
- In FY2025, capital expenditures decreased 32.1% year-over-year.
- Peak capital expenditures was recorded in FY2016.
- Lowest capital expenditures in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -47.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $116.1K | -32.1% |
| FY2024 | $171.0K | +0.0% |
| FY2023 | $171.0K | -35.5% |
| FY2022 | $265.2K | +765.1% |
| FY2021 | $30.7K | -14.0% |
| FY2020 | $35.6K | +176.9% |
| FY2019 | $12.9K | +255.8% |
| FY2018 | $3.6K | -98.1% |
| FY2017 | $188.8K | -53.7% |
| FY2016 | $408.1K | +142.4% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026